Trials / Conditions / Urothelial Carcinoma (UC)

Urothelial Carcinoma (UC)

13 registered clinical trials studyying Urothelial Carcinoma (UC) — 13 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors NCT07518043	Shanghai Henlius Biotech	Phase 1
Not Yet Recruiting	Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer NCT07525349	Assiut University	—
Recruiting	A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413	IDEAYA Biosciences	Phase 1
Enrolling By Invitation	Artificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology NCT07454941	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	—
Not Yet Recruiting	Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors NCT07439120	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	EARLY_Phase 1
Recruiting	Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial Carcinoma NCT07441499	Tianjin Medical University Second Hospital	—
Not Yet Recruiting	Randomized Trial of stAndard of Care With or Without Metastases-directed Stereotactic Body Radiation Therapy i NCT07413523	Istituto Clinico Humanitas	N/A
Recruiting	Korean Prospective Upper Tract Urothelial Carcinoma Cohort NCT07452432	Samsung Medical Center	—
Enrolling By Invitation	PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors NCT07023848	Affiliated Hospital of Jiangnan University	EARLY_Phase 1
Enrolling By Invitation	The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Mali NCT07023861	Affiliated Hospital of Jiangnan University	EARLY_Phase 1
Recruiting	A Patient-Directed Mobile Tool to Streamline the QoL Assessment and Monitoring in Urothelial Carcinoma NCT06982794	IRCCS San Raffaele	—
Recruiting	A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, NCT05706129	ITM Oncologics GmbH	Phase 1 / Phase 2
Recruiting	Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors NCT05176483	Exelixis	Phase 1